Abstract
The risk of developing long-term diabetes mellitus–related complications (retinopathy, nephropathy, neuropathy, cardiovascular disease, and stroke) increases as glycated hemoglobin (A1C) levels exceed 6.5%. All patients with diabetes should be provided with an individualized target A1C based on factors such as age, duration of disease, risk of hypoglycemia, existing comorbidities, available resources, life expectancy, and cardiovascular risk. A delay of therapeutic intensification of just 2 years from the time of diagnosis can expose a patient to “glycemic burden” and a 61% increased risk of cardiovascular complications.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
